Current challenges in the management of follicular lymphoma. [Review] 

 -  2017 
<br/><br/> Although typically indolent in nature, follicular lymphoma remains an ongoing challenge for practicing oncologists. While response rates >90% can be achieved with rituximab-based chemoimmunotherapy in advanced stage patients, the complete remission rates are substantially lower and patients inevitably relapse. The inability to achieve a complete remission and an early progression of disease have recently been determined to be indicative of poorer long-term outcomes. A greater understanding of the pathogenesis of follicular lymphoma has enabled the development of targeted therapies, which may improve standard treatment approaches. Examples include lenalidomide and obinutuzumab, which are currently in front-line Phase III investigation. Other therapies of interest include small molecule inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>2045-1393 
<br/><br/><label>Standard No.: </label>10.2217/ijh-2017-0003 [doi] PMC6171972 [pmc] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>PubMed-not-MEDLINE -- Not indexed
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Hematology and Oncology
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Review